We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Collagen Solutions Plc | LSE:COS | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.625 | 6.25 | 7.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCOS
RNS Number : 6124Q
Collagen Solutions PLC
22 October 2019
Collagen Solutions plc
("Collagen Solutions" or the "Company")
Trading Update & Notice of Results
Collagen Solutions Plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, provides an update on trading for the six months to 30 September 2019.
Revenue is expected to be GBP2.23m (H1 2018: GBP1.95m), representing a 14.4% increase on the prior year, driven in particular by continuing momentum in our newly established tissue business.
New customer acquisition continues with four new customer contracts and 10 new customers.
In June 2019, the Company completed a fundraise of GBP5.96m gross of costs made up of a strategic investment by Rosen's Diversified Inc of GBP4.18 million, a placing with existing and new investors of GBP1.25 million and an open offer totalling GBP0.53 million. The funds are being used to further customer and proprietary product development, expand contract manufacturing activities and capabilities and for working capital including the repayment of the Norgine Ventures Bond Facility.
The Company continues to execute on its customer product development milestones, having signed new development customers, which represent additional future contract manufacturing opportunities, once these products are approved and launched. In addition, the Company remains engaged in the process to address questions from its notified body for the ChondroMimetic(R) CE mark consistent with our previously stated plans.
Jamal Rushdy, CEO, commented: "We are pleased to report the third consecutive six-month period of double-digit sales growth demonstrating consistent performance to our expectations by the Collagen Solutions global team. Our core business remains strong and our initiative to increase capacity is on track to meet the anticipated higher demand for both collagen and tissue products."
The Company will announce its interim results for the six months to 30 September 2019 on Tuesday, 3 December 2019.
Collagen Solutions Plc Jamal Rushdy, CEO Via Walbrook Hilary Spence, CFO Cenkos Securities Plc (Nominated Adviser and Broker) Giles Balleny (Corporate Finance) Tel: 0207 397 8900 Max Gould Walbrook PR Ltd Tel: 020 7933 8780 or collagen@walbrookpr.com Anna Dunphy Mob: 07876 741 001
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, tissue engineering, and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic(R). The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
For more information go to: www.collagensolutions.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCMBBATMBATBML
(END) Dow Jones Newswires
October 22, 2019 02:00 ET (06:00 GMT)
1 Year Collagen Solutions Chart |
1 Month Collagen Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions